Johnson & Johnson ( JNJ ) probe.

Senate Joins Probe Into The J&J Recall Scandal

Make a commentBy Ed Silverman // May 25th, 2010 // 12:03 pm

tom-harkinJust two days before the House holds a hearing into the unusually large number of products recalled by Johnson & Johnson, the Senate Health, Education, Labor and Pensions (HELP) Committee wrote the FDA in search of additional info concerning actions taken by both the agency and the health care giant.

“I am especially concerned because so many of the drugs at issue in this recall were intended for infants and children,” Harkin (see photo) wrote in his letter to FDA commish Margaret Hamburg. He did not indicate, however, plans to hold a hearing. The House Committee on Oversight and Government Reform will question FDA deputy commish Josh Sharfstein and Colleen Giggins, who heads J&J’s global consumer business on Thursday (see this).

J&J’s McNeil unit was cited for quality-control problems that affected about 40 over-the-counter meds for infants and children, and failed to properly follow up complaints that certain batches of its Tylenol Arthritis Relief Caplets had a musty smell. Earlier this month, J&J closed down a McNeil facility in Fort Washington, Pennsyvlania, to cope with the problem. UPDATE: Meanwhile, J&J added another blog post this afternoon to tell employees – and the rest of us – about its efforts, which include replacing or shifting some McNeil managers.

Be Sociable, Share!
You can leave a response, or trackback from your own site.

Leave a Reply


Design by Aaron Melvin